Department Endocrinologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Cancer Invest. 2013 Mar;31(3):190-6. doi: 10.3109/07357907.2013.775293.
Temozolomide (TMZ) has been proposed as a therapeutic option in aggressive pituitary tumors. Among the published cases, GH expressing tumors were rare. We describe a patient with initially benign silent GH adenoma that transformed into an aggressive GH secreting tumor resistant to usual therapy. MGMT expression was high and the MGMT promoter was unmethylated. Before this aggressive course, patient received three cycles of TMZ; no response was observed. Four cases of GH aggressive tumor treated by TMZ have been reported. Response to TMZ was observed in one of these four patients. Predictive factors of failure of TMZ remain unclear.
替莫唑胺 (TMZ) 已被提议作为侵袭性垂体肿瘤的治疗选择。在已发表的病例中，生长激素 (GH) 表达肿瘤较为罕见。我们描述了一例最初为良性无功能 GH 腺瘤的患者，该腺瘤转变为对常规治疗耐药的侵袭性 GH 分泌性肿瘤。MGMT 表达较高，MGMT 启动子未甲基化。在这种侵袭性病程之前，患者接受了三个周期的 TMZ 治疗；未观察到反应。已有报道称，TMZ 治疗了 4 例 GH 侵袭性肿瘤。这 4 例患者中有 1 例观察到 TMZ 有反应。TMZ 治疗失败的预测因素尚不清楚。
